DFTX at a glance
Definium Therapeutics, Inc. (DFTX, SEC CIK 1813814) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as September 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Definium Therapeutics, Inc. (DFTX) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sullivan Mark on September 25, 2026 of 14,051 shares at $36.57 per share.
- In the last 90 days, DFTX insiders reported 0 open-market purchases ($0) and 6 open-market sales ($3.0M) on Form 4, a net sale of $3.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$3.0M
- 13F holders
- 28 funds
- $1.2B · −5 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: late-stage clinical biopharma developing psychedelics-based treatments for brain health disorders
- New emphasis on Phase 3 trials for DT120 ODT targeting GAD and MDD; initiated DT402 Phase 2a trial for autism spectrum disorder in late 2025
- Strategic shift: rebranded from MindMed to Definium Therapeutics in January 2026, began trading as “DFTX” on Nasdaq
- Quantitative highlight: DT120 Phase 2b GAD trial showed 7.6-point HAM-A improvement vs placebo (p<0.0004) with 65% response rate sustained to 12 weeks
- Noteworthy: FDA granted Breakthrough Therapy designation for DT120 in GAD and UK’s MHRA issued Innovation Passport designation in 2024
Risk Factors
- Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026
- Geopolitical/macro risk: Clinical trial enrollment and drug supply dependent on U.S. regulations and foreign currency exchange fluctuations affecting expenses
- Operational risk: Dependence on contract research and manufacturing organizations for clinical trials and cGMP-compliant product supply
- Competitive risk: Psychedelic drug market includes competitors developing alternative therapies for brain health disorders (no named competitor disclosed)
- Financial risk: $411.6M cash as of Dec 31, 2025, expected funding into 2028, but reliance on future equity/debt raises could dilute shareholders or impose restrictive covenants
Management Discussion & Analysis
- Forward-looking statements mentioned with general risk disclosure but no specific guidance or outlook
AI summary of the DFTX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors during the three months ended September 30, 2026
- Existing 2025 Form 10-K risks remain applicable to business condition, results of operations and cash flows
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product candidates commercialized
- Operating margin not applicable, operating loss $72.3M vs $45.7M YoY
- Best-performing program: DT120 GAD, external costs $14.7M vs $16.2M YoY
- Cash, equivalents and investments approximately $1.0B; operating cash use $148.4M for nine months
- Cash runway into 2030; R&D expenses expected to increase throughout 2026
AI summary of the DFTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended September 30, 2026 results announced on November 9, 2026
- Press release includes recent corporate highlights and conference call information
Item EX-99.1: Item EX-99.1
- Positive Phase 3 Voyage and Panorama results in GAD, with placebo-adjusted HAM-A improvements of 5.4 and 5.1 points
- DT120 ODT received FDA Breakthrough Therapy designation for MDD, supporting regulatory momentum toward a first-half 2027 NDA filing
Item EX-99.1: Item EX-99.1
- Panorama met primary and all key secondary endpoints in 245-patient Phase 3 GAD trial, reinforcing DT120 ODT’s regulatory case
- HAM-A placebo-adjusted improvement reached 5.1 points at Week 12, with p<0.0001 and Cohen’s d=0.64
Item 8.01: Other Events
- Presentation announces Panorama topline data, a potentially material clinical-development update
- Investors should review Exhibit 99.2 for efficacy, safety, endpoint and trial-result details
Item 7.01: Regulation FD Disclosure
- Positive topline Phase 3 Panorama data for DT120 ODT in generalized anxiety disorder
- Clinical update marks a potentially important development for Definium’s lead therapeutic program
Item EX-99.2: Item EX-99.2
- Phase 3 Panorama met all primary and key secondary endpoints in GAD, strengthening DT120 ODT’s path toward regulatory filing
- DT120 ODT 100 µg improved HAM-A versus placebo by 5.1 points at week 12 and 5.3 points at week 1, both p<0.0001
Item 8.01: Other Events
- FDA breakthrough designation granted to DT120 ODT for major depressive disorder
- Potentially faster FDA development and review pathway for DT120 ODT
Item EX-99.1: Item EX-99.1
- FDA Breakthrough Therapy designation for DT120 in MDD, accelerating potential development and review
- Phase 3 Emerge: 8.1-point placebo-adjusted MADRS improvement at Week 6, p<0.0001
AI summaries of DFTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DFTX
Don't miss the next DFTX filing
- Alerts as it files. A push when DFTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DFTX, by share count.
- Ask anything. An AI agent that reads every DFTX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sullivan Mark | Sell | Sep 25, 2026 | 14,051 | $36.57 |
| Karlin Daniel | Sell | Sep 25, 2026 | 10,853 | $36.57 |
| Barrow Robert | Sell | Sep 25, 2026 | 31,550 | $36.57 |
| Wiley Matthew T. | Sell | Sep 25, 2026 | 3,097 | $36.57 |
| Roberts Brandi | Sell | Sep 25, 2026 | 3,377 | $36.57 |
| Vallone Carol A | M | Sep 18, 2026 | 1,086 | $35.52 |
| Vallone Carol A | M | Sep 18, 2026 | 1,086 | - |
| Krebs Andreas | M | Sep 18, 2026 | 1,629 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$93.9M | -$103.9M | -$166.3M | |
| Net Income | -$95.7M | -$108.7M | -$183.8M | |
| Balance Sheet | ||||
| Total Assets | $124.5M | $302.2M | $440.1M | |
| Equity | $78.1M | $241.4M | $332.3M | |
| ROE | -122.5% | -45.0% | -55.3% | |
| Per Share | ||||
| EPS | $-2.44 | $-1.54 | $-2.06 | |
| Cash Flow | ||||
| Operating CF | -$64.4M | -$79.1M | -$131.6M | |
Source: XBRL data in Definium Therapeutics, Inc. (DFTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DFTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $1.20B |
| Q2 2026 | 33 | $1.76B |
| Q1 2026 | 27 | $459.5M |
| Q4 2025 | 1 | $700,000 |
- Invesco Ltd+730.3K (+800%)
- BlackRock+539.8K (+5%)
- Bank of America Corp+353.9K (+215%)
- State Street Corp+235.7K (+8%)
- Morgan Stanley+229.8K (+51%)
- Two Sigma Investments−695.9K (-75%)
- T. Rowe Price Group−285.8K (-6%)
- Millennium Management−225.6K (-85%)
- D.E. Shaw & Co−156.1K (-49%)
- Wells Fargo & Co−80.8K (-66%)
- FMR LLC (Fidelity)−4.75M
- Citadel Advisors LLC−1.69M
- Blackstone Group−561.6K
- Mangrove Partners−9.1K
- Marex Group plc−6.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 89 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DFTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis |
Related Health Care companies
- BTMD · biote Corp.Medicinal Chemicals & Botanical Products
- FTLF · FITLIFE BRANDS, INC.Medicinal Chemicals & Botanical Products
- MDWD · MediWound Ltd.Medicinal Chemicals & Botanical Products
- NAGE · Niagen Bioscience, Inc.Medicinal Chemicals & Botanical Products
- USNA · USANA HEALTH SCIENCES INCMedicinal Chemicals & Botanical Products
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
DFTX SEC filings: frequently asked questions
Are DFTX insiders buying or selling?
In the last 90 days, Definium Therapeutics, Inc. (DFTX) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $3.0 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DFTX stock?
As of September 30, 2026, the largest Definium Therapeutics, Inc. (DFTX) holders among the 13F filers tracked by SignalX were BlackRock ($448.1 million), T. Rowe Price Group ($166.2 million), State Street Corp ($125.6 million), Goldman Sachs Group ($73.7 million), Vanguard Portfolio Management LLC ($63.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in DFTX's latest 10-K?
In the 10-K filed February 26, 2026, Definium Therapeutics, Inc. (DFTX) flagged: Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026. Geopolitical/macro risk: Clinical trial enrollment and drug supply dependent on U.S. regulations and foreign currency exchange fluctuations affecting expenses. (AI summary of the Risk Factors section.)
What did DFTX report in its latest 8-K?
Definium Therapeutics, Inc. (DFTX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended September 30, 2026 results announced on November 9, 2026.
What are the latest DFTX SEC filings?
Definium Therapeutics, Inc. (DFTX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on September 29, 2026.
What is DFTX's SEC CIK number?
Definium Therapeutics, Inc. (DFTX)'s SEC Central Index Key (CIK) is 1813814. EDGAR lists every DFTX filing under that number.
Ask anything about DFTX
The research agent reads DFTX's filings, financials, insider trades and 13F holders, then answers with sources.